Domo signs strategic collaboration agreement with AWS for AI solutions
FLORHAM PARK, N.J. - Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), which has seen its stock surge over 87% in the past six months according to InvestingPro data, announced today that an upcoming Schedule 13D filing by Frazier Life Sciences does not represent any reduction in Frazier’s ownership position in the company.
The biopharmaceutical firm explained that while the filing, expected later today, will show administrative changes to Frazier’s reporting approach, these modifications only affect how holdings are broken out between funds and persons. The company noted that differences in the treatment of warrants may reduce certain percentages in the updated filings.
"These differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares," Phathom stated in its press release.
Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases. The company has exclusive rights to vonoprazan, a potassium-competitive acid blocker (PCAB) marketed in the United States under the brand names VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK.
The company’s products are used for various gastrointestinal conditions, including the relief of heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and treatment of H. pylori infection.
The clarification comes as part of the company’s regular investor communications regarding significant ownership filings. With analyst price targets ranging from $12 to $29, the stock presents interesting potential for investors seeking exposure to the biotech sector.
In other recent news, Phathom Pharmaceuticals reported its second-quarter 2025 earnings, surpassing revenue expectations. The company achieved a revenue of $39.5 million, exceeding the projected $36.38 million, which represents an 8.58% surprise. Additionally, Phathom Pharmaceuticals reported earnings per share at a loss of $0.79, better than the anticipated loss of $0.91. These results indicate a stronger-than-expected financial performance for the quarter. The positive earnings report has been a focal point for investors, reflecting a more favorable outlook. While the company’s stock price experienced a rise in pre-market trading, this article focuses on the earnings data itself. These developments come amid broader market interest in the company’s financial health. The company’s performance has drawn attention from various analyst firms, though specific upgrades or downgrades were not mentioned in the recent reports.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.